Market Overview

Glancy Prongay & Murray LLP Reminds Investors of Lead Plaintiff Deadline in the Class Action Lawsuit Against Recro Pharma, Inc. (REPH)

Share:

Glancy
Prongay & Murray LLP
("GPM") reminds investors of the July
30, 2018
deadline to file a lead plaintiff motion in the class
action filed on behalf of investors that purchased Recro Pharma, Inc.
("Recro Pharma" or the "Company") (NASDAQ: REPH)
securities between July 31, 2017, and May 23, 2018, inclusive
(the "Class Period").

If you are a shareholder who suffered a loss, click here to
participate.

The complaint filed in this class action alleges that, Recro Pharma made
false and misleading statements to the marketplace. The Company's lead
product, IV meloxicam, was unlikely to receive FDA approval due to
lacking sufficient supporting clinical data to demonstrate significant
clinical benefits. As a result, Recro Pharma's public statements were
materially false and misleading throughout the class period and did not
accurately reflect the results of business operations and the financial
health of the Company.

On May 24, 2018, Recro Pharma announced that it received a Complete
Response Letter ("CRL") from the U.S. Food and Drug Administration
("FDA") regarding the Company's New Drug Application ("NDA") for IV
meloxicam. In the CRL, the FDA informed the Company that the FDA was
"unable to approve the application in its current form" because "data
from ad hoc analyses and selective secondary endpoints suggest that the
analgesic effect does not meet the expectations of the FDA" and "the CRL
raised CMC related questions on extractable and leachable data provided
in the NDA." On this news, Recro Pharma's share price fell $6.79 per
share, or 54.7%, to close at $5.63 per share on May 24, 2018, thereby
injuring investors.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased shares of Recro Pharma during the Class Period you may
move the Court no later than July 30, 2018 to ask the Court to
appoint you as lead. To be a member of the Class you need not take any
action at this time; you may retain counsel of your choice or take no
action and remain an absent member of the Class. If you wish to learn
more about this action, or if you have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East,
Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at
888-773-9224, by email to shareholders@glancylaw.com,
or visit our website at www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

View Comments and Join the Discussion!